Plain-English translation of NCT06612710 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing NouvSoma001, a new treatment made from particles derived from human nerve cells, to see if it can help people recover from ischemic stroke (a stroke caused by a blood clot). Researchers will give the medication or a placebo as daily injections for one week and then monitor participants to see if the treatment is safe and helps improve stroke recovery. The study will first test different dose levels in a small group, then give the most promising dose to a larger group of participants.
Ischemic stroke can cause lasting disability, and current treatments have limited ability to help people recover lost brain function. This trial exists to test whether this medication, which is designed to support nerve cell health and repair, might offer a new way to help stroke patients recover better.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive daily injections of either the medication or a placebo (an inactive substance) for 7 consecutive days. The study involves two parts: the first part tests whether the medication is safe at different dose levels in a small group, and the second part gives the safest effective dose to a larger group of participants. You will need to attend follow-up visits and brain imaging scans to allow researchers to monitor your safety and track any changes in your stroke symptoms over time.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
China